Novo Nordisk Partners with Anthropic to Accelerate Drug Discovery
News related to:Novo Nordisk · 1 min read
Novo Nordisk, a global healthcare company, has announced a collaboration with Anthropic, a leading artificial intelligence (AI) firm, to accelerate drug discovery and advance AI-driven software development. The partnership aims to help Novo Nordisk discover and develop new medicines more efficiently, leveraging Anthropic's advanced AI models and Claude Science.
According to Mike Doustdar, president and CEO of Novo Nordisk, this collaboration is part of the company's broader ambition to become the world's most AI-driven healthcare company.
The collaboration will focus on addressing key drug discovery challenges identified by Novo Nordisk's scientists and computational teams. Specific workflows in R&D will be tested using Claude Science, with the goal of developing targeted solutions for scientific challenges and improving biological reasoning. Doustdar emphasized that AI can increase productivity in R&D and compress the path from research to marketed product. Additionally, Anthropic's frontier models will be used to strengthen AI-driven software development, a key enabler for scaling AI across the company.
Dario Amodei, co-founder and CEO of Anthropic, highlighted the potential of AI in accelerating research timelines and improving outcomes.
The collaboration has been designed with robust data governance and human oversight to ensure AI is applied responsibly and in line with Novo Nordisk's ethical and compliance standards. This partnership is expected to drive innovation and enhance the company's ability to develop new treatments and therapies for chronic diseases.
Novo Nordisk, founded in 1923, is committed to driving change for lasting health. The company's global team of over 67,000 employees is dedicated to developing treatments and support that help millions of people make progress they can see, feel, and sustain. Through partnerships, programmes, and investments, Novo Nordisk is working to prevent disease, expand access to treatments, and reduce its environmental impact to help even more people live healthier lives.